Israel Englander Cytokinetics Inc Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Cytokinetics Inc stock. As of the latest transaction made, Millennium Management LLC holds 11,800 shares of CYTK stock, worth $529,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,800

Previous 60,605 80.53%

Holding current value

$529,938

Previous $3.2 Million 82.65%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$46.36 - $58.62 $467,308 - $590,889	-10,080 Reduced 16.63%	50,525 $2.38 Million
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $3.1 Million - $3.65 Million	60,605 New	60,605 $3.2 Million
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $24.8 Million - $42 Million	-388,431 Reduced 32.39%	810,910 $56.9 Million
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $18.4 Million - $57 Million	682,876 Added 132.22%	1,199,341 $100 Million
Q2 2023 Aug 14, 2023	BUY	$32.62 - $40.75 $9.58 Million - $12 Million	293,770 Added 131.92%	516,465 $16.8 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $1.16 Million - $1.59 Million	34,726 Added 18.47%	222,695 $7.84 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $508,077 - $725,966	-14,204 Reduced 7.03%	187,969 $8.61 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $4.64 Million - $6.57 Million	120,431 Added 147.33%	202,173 $9.8 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $2.33 Million - $3.36 Million	68,637 Added 523.75%	81,742 $3.21 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $6.68 Million - $10.3 Million	-224,702 Reduced 94.49%	13,105 $482,000
Q4 2021 Feb 14, 2022	SELL	$34.35 - $46.38 $9.35 Million - $12.6 Million	-272,180 Reduced 53.37%	237,807 $10.8 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $1.08 Million - $2.08 Million	58,105 Added 12.86%	509,987 $18.2 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $9.28 Million - $12.7 Million	-468,893 Reduced 50.92%	451,882 $8.94 Million
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $665,195 - $919,883	35,821 Added 4.05%	920,775 $21.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.26 - $28.61 $3.23 Million - $6.06 Million	211,767 Added 31.46%	884,954 $18.4 Million
Q3 2020 Nov 16, 2020	SELL	$20.58 - $28.96 $11.2 Million - $15.8 Million	-544,594 Reduced 44.72%	673,187 $14.6 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $3.05 Million - $6.73 Million	-273,146 Reduced 18.32%	1,217,781 $28.7 Million
Q1 2020 May 14, 2020	SELL	$8.75 - $16.3 $9.46 Million - $17.6 Million	-1,080,630 Reduced 42.02%	1,490,927 $17.6 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $11.84 $4.6 Million - $6.85 Million	578,539 Added 29.03%	2,571,557 $27.3 Million
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $312,524 - $411,597	28,884 Added 1.47%	1,993,018 $22.7 Million
Q2 2019 Aug 15, 2019	BUY	$7.95 - $11.25 $14.4 Million - $20.4 Million	1,809,333 Added 1168.81%	1,964,134 $22.1 Million
Q2 2019 Aug 14, 2019	SELL	$7.95 - $11.25 $6.12 Million - $8.65 Million	-769,200 Reduced 83.25%	154,801 $2.26 Million
Q1 2019 May 14, 2019	BUY	$5.95 - $10.19 $5.26 Million - $9.01 Million	884,297 Added 2227.22%	924,001 $7.48 Million
Q4 2018 Feb 14, 2019	SELL	$5.91 - $9.29 $1.12 Million - $1.76 Million	-189,213 Reduced 82.66%	39,704 $251,000
Q3 2018 Nov 14, 2018	SELL	$6.4 - $9.85 $1.49 Million - $2.29 Million	-232,816 Reduced 50.42%	228,917 $2.26 Million
Q2 2018 Aug 14, 2018	BUY	$6.9 - $9.9 $2.48 Million - $3.56 Million	359,561 Added 351.92%	461,733 $3.83 Million
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $543,182 - $758,192	75,442 Added 282.24%	102,172 $736,000
Q4 2017 Feb 14, 2018	BUY	$7.25 - $15.65 $193,792 - $418,324	26,730	26,730 $218,000

Others Institutions Holding CYTK

# of Institutions

397

Shares Held

122M

Call Options Held

3.46M

Put Options Held

1.86M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.23B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account